



Tanvex BioPharma Enters Exclusive Distribution Agreement for Nypozi (filgrastim) in Canada

May 16, 2023

Tanvex BioPharma, Inc., has announced that its subsidiary, Tanvex BioPharma USA, Inc. has entered into a distribution agreement with Sandoz AG for Nypozi (filgrastim) in Canada. Under the terms of the deal, Tanvex will receive an upfront payment, payments for supply and contingent payments based on sales and profit from the product. All other terms of the agreement are confidential.

Dr. Yun Yen, CEO of Tanvex BioPharma, Inc. stated: “I am extremely excited to announce this partnership with Sandoz in Canada. With Sandoz’s strong market presence and biosimilar experience in Canada, we believe Nypozi is positioned well for a successful launch. The companies are actively working on launch plans and hope to launch Nypozi in Canada by the end of the year.”

Nypozi is a registered trademark of Tanvex BioPharma, Inc. in Canada; trademark is pending in the United States.

About Tanvex

Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.